| |
|
|
| |
Transdermal CNS Therapeutics
Products, Pipeline Candidates, Markets,
Forecasts
|
Publication: May 2012
Product Code: TCNS407F
|
Current disease trends point to increasing morbidity and
mortality associated with CNS ailments in the general
population. These trends include the growing incidence of
neurological disorders associated with longevity and aging,
and significant increases in the number of children
diagnosed with autism. Because diseases of the central
nervous system often result in compromised cognitive and/or
motor skills that can increase the level of involuntary
non-compliance with therapeutic protocols, transdermal
delivery of drugs targeting CNS disorders is generally
viewed as a method that can increase patient safety and
improve outcomes. In addition to the handful of FDA-approved
transdermal CNS products, more than a dozen companies are
currently pursuing a range of APIs in transdermal delivery
systems that target neurological and CNS conditions. While
none of these development-stage candidates is curative, the
benefits they can offer in terms of patient ease-of-use,
product safety and overall quality-of-care are expected to
result in reduced morbidity and more effective symptom
management for afflicted patients. |
|
Highlights |
· Analyzes and evaluates
the global market opportunity for transdermal CNS drugs and assesses the probable impact of evolving
regulatory, economic and demand factors
· Assesses transdermal
products approved or in development for the delivery of
therapeutic drugs for treating central nervous system
indications
· Provides detailed
descriptions of central nervous system treatment segments,
market factors, and business strategies
· Forecasts transdermal
CNS product demand to 2016 by geographic
region and product segment
· Profiles sector companies,
their product development activities,
supply chain partners, business
strategies, and collaboration partners
|
|
Summary of Contents |
Executive Summary
The Current CNS Drug
Therapeutics Market
Unmet Needs in CNS Disease
Treatment
The Opportunity for Transdermal
Delivery of CNS Therapeutics
The CNS
Therapeutics Market Opportunity
Changes and
Trends in Incidence and Morbidity
The Demand
Picture for CNS Therapeutics
Competitive
Landscape
Factors Limiting Growth
Transdermal Drug Delivery to the CNS
Patch
Designs and Construction
Transdermal Patch
Manufacturing and Packaging
The Patch
Manufacturing Ecosystem
CNS Patch Economics
Passive vs Active Delivery Systems
The Global
Market for Transdermal CNS Therapeutics –Disease
Segment Analysis
ADHD
Alzheimer’s Disease
Dementia
Depression
Migraine
Nausea
Parkinson’s Disease
Restless Leg Syndrome
Schizophrenia
Transdermal CNS Drug Product
Analysis and Market Assessments
FDA Approved
Transdermal CNS Prescription Products
MAO
Inhibitors
Cholinergic Agents
Dopamine
Agonists
CNS Stimulants
5-HT3 Receptor
Antagonists
Non-FDA Approved Commercial
Transdermal CNS Products
Non-U.S. Regional
Product Assessment & Market Impact
Strategic
Factors and Branding Issues
Development-Stage
Transdermal CNS Prescription Products
AChE
Inhibitors
Cholinergic Agents
Dopamine
Agonists
5-HT3 Receptor Antagonists
Serotonin
Agonists
Other Drug Classes
Transdermal
CNS Therapeutics Market Data & Forecasts
Market Factors
Regulations and Approvals
Clinical Trials
Indications Prescribing
Guidelines and Off-Label Prescribing
Rx-to-OTC
Switching
Skin Patch Revenue Models
Market Participant Profiles
|
|
|
|
|
